Bailout Program Extended
On the upside
J. P. Morgan upgraded RealNetworks (Nasdaq: RNWK) saying that the company should receive a favorable ruling in its arbitration with VeriSign (NYSE: VRSN).
Avanir Pharmaceuticals (Nasdaq: AVNR) reported upbeat results from a Phase III clinical trial of its amyotrophic lateral sclerosis treatment Zenvia.
Citigroup analyst Michael Rollins upgraded Sprint (NYSE: S) and lifted his price target on the company saying that sales should improve next year and that the company may seek a merger deal.
On the downside
Westport Innovations (Nasdaq: WPRT) priced its offering of 4.75 million common shares at $10.50 per share.
MedAssets (Nasdaq: MDAS) disappointed with a 2010 forecast that fell short of estimates prompting a downgrade.
Energy XXI (NYSE: EXXI) priced its offering of $171 million in common shares and $100 million in convertible preferred stock.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 3 on the NYSE and by a margin of more than 2 to 1 on Nasdaq. The Russell 2000 which tracks small cap stocks added a fraction to 597.

